

Diabetes mellitus and renal failure: Prevention and management

Hamid Nasri, Mahmoud Rafeian-Kopaei¹

Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, ¹Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

Nowadays, diabetes mellitus (DM) and hypertension are considered as the most common causes of end-stage renal disease (ESRD). In this paper, other than presenting the role of DM in ESRD, glucose metabolism and the management of hyperglycemia in these patients are reviewed. Although in several large studies there was no significant relationship found between tight glycemic control and the survival of ESRD patients, it is recommended that glycemic control be considered as the main therapeutic goal in the treatment of these patients to prevent damage to other organs. Glycemic control is perfect when fasting blood sugar is less than 140 mg/dL, 1-h postprandial blood glucose is less than 200 mg/dL, and glycosylated hemoglobin (HbA1c) is 6-7 in patients with type 1 diabetes and 7-8 in patients with type 2 diabetes. Administration of metformin should be avoided in chronic renal failure (CRF) because of lactic acidosis, the potentially fatal complication of metformin, but glipizide and repaglinide seem to be good choices.

Key words: Chronic kidney disease, diabetes mellitus (DM), World Kidney Day

How to cite this article: Nasri H, Rafeian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. *J Res Med Sci* 2015;20:1112-20.

INTRODUCTION

End-stage renal disease (ESRD) is a condition in which the kidneys are no longer able to work properly in response to the needs of day-to-day life. ESRD usually occurs following chronic kidney disease and is one of the most important and life-threatening diseases. It imposes a huge mental and economic burden on societies.^[1-18]

Nowadays, diabetes and hypertension have become the most common causes of ESRD in both developed and developing societies.^[4,5,19] In a study conducted in the USA, diabetes and hypertension were responsible for more than 50% of cases of ESRD,^[19] and in a study conducted in Khuzestan, Iran, diabetes was the most common cause of disease and glomerulonephritis was responsible for about 10% of cases.^[4]

According to the high prevalence of DM among patients with ESRD, there is a huge need to learn more about

its prevention and management. Hence, other than presenting the role of DM in ESRD and the preventive choices, this paper was designed to review the glucose metabolism and management of hyperglycemia in these patients.

IMPACT OF DIABETES MELLITUS AND RENAL FAILURE ON EACH OTHER

DM is a metabolic disease that causes renal failure, and renal failure increases the need for insulin in diabetic patients.^[4,20-31] The accumulation of uremic toxins and increased parathyroid hormone levels in patients with chronic renal failure (CRF) cause insulin resistance in tissues, particularly skeletal muscle tissues. This has been attributed to damage in the process after insulin binding to its receptors, which disturbs glucose metabolism and glycogen production.^[20,21,24,27,30] It also seems that anemia caused by CRF has an impact on insulin resistance, and the correction of anemia by erythropoietin has been shown to increase insulin sensitivity in the body.^[32]

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Access this article online

Quick Response Code:



Website:

www.jmsjournal.net

DOI:

10.4103/1735-1995.172845

Address for correspondence: Prof. Mahmoud Rafeian-Kopaei, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. E-mail: rafeian@skums.ac.ir

Received: 13-04-2015; **Revised:** 14-09-2015; **Accepted:** 20-11-2015

Insulin secretion is also reduced in patients with CRF, which appears to be due to metabolic acidosis, elevated levels of parathyroid hormone, and decreased level of vitamin D.^[33,34]

It should be noted that despite the decreased insulin secretion and impaired tissue sensitivity to insulin that occurs in patients with CRF, most nondiabetic CRF patients do not have hyperglycemia unless they are genetically predisposed.^[20,24]

In advanced stages of CRF, when the glomerular filtration rate (GFR) become less than 15-20 cc/min, degradation and renal clearance of insulin decreases, which is clinically important in the treatment of patients with diabetes.^[20] Although insulin resistance increases the insulin requirement, decreased insulin degradation reduces the need for administration of insulin in diabetic patients with advanced CRF or even resolves it in patients with type 2 diabetes. This may increase the risk of hypoglycemia. Renal replacement therapy, hemodialysis, and peritoneal dialysis relatively resolve this problem in most patients and based on the amount of clinical improvement, the insulin requirements change. Increased appetite and food intake resulting from the replacement therapy and alleviation of uremic symptoms also change insulin requirements.^[24]

IMPACT OF OXIDATIVE STRESS ON DIABETES MELLITUS AND RENAL FAILURE

Under stressful conditions, reactive oxygen species (ROS) are overproduced, inducing oxidative stress. Hence, oxidative stress is due to an imbalance between free radical formation and antioxidant defense capacity.^[35-41] The result of this oxidative stress would be the induction of chronic hard-to-cure diseases such as diabetes,^[42-47] hypertension,^[48,49] cardiovascular disorders,^[50-52] cancer,^[53-60] cognitive diseases,^[61-64] and pain,^[65-69] or exacerbation of some other diseases such as infectious disorders.^[70-79]

Oxidative stress also plays a crucial role in the development of diabetic kidney disease.^[80-85] The number of patients with diabetic kidney disease is increasing worldwide. Increase in the level of ROS, which induces oxidative stress, has been considered the major cause of renal failure. Other than diabetes, renal failure itself also increases oxidative stress.^[86] There are a number of macromolecules that have been shown to be implicated in the increased generation of ROS, including specific defects in the polyol pathway, glycolysis, advanced glycation, xanthine oxidase, reduced nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase, and uncoupling of nitric oxide synthase, which are the contributors of diabetic kidney disease. The morphologic characteristics of diabetic nephropathy include tubular atrophy, glomerular hypertrophy, arteriolar

thickening, basement membrane thickening, mesangial expansion, and interstitial fibrosis, which are among the microvascular complications of diabetes.^[87]

The increase in ROS is due to both increased production and decreased and/or inadequate antioxidant availability or function. Recent research studies have determined that both high glucose-induced changes in antioxidant function and high glucose-induced cellular ROS production contribute to the diabetes induction of renal failure. Treatments that target one or more diabetes-induced alterations for the regulation of ROS might lead to effective protection against or treatment of diabetic kidney disease. In this regard, the use of antioxidants seems to be effective in diabetes and protection against kidney disease.^[88-90]

ROLE OF ANTIOXIDANTS IN CONTROL OF DIABETES AND KIDNEY DISEASE

Buffering the generation of ROS or consumption of these compounds might be a promising therapeutic approach to ameliorate diabetes and/or renal damage.^[90-93]

Antioxidants have been shown to be effective in a lot of ROS-induced diseases.^[94-105] The role of antioxidant therapy in diabetes and/or renal failure in humans is not clear, but there are a number of preclinical reports showing the effectiveness of antioxidants in the prevention and treatment^[106-113] of diabetes^[13,109,114-116] as well as renal failure.^[117]

Antioxidants with plant origins have been shown to be a better choice for this purpose and a lot of plants exhibit antioxidant activity. In this regard, it is better that we try using plants that have shown good results for controlling both DM and kidney disease.^[118-123]

NEW APPROACHES FOR CONTROL OF RENAL FAILURE

Control of diabetes and early treatment for the risk factors of diabetes are very important in preventing or delaying nephropathy. Control of hypertension with medications that modulate the renin-angiotensin system (RAS) has been shown to decrease the incidence as well as progression of diabetic kidney disease.^[122] The consumption of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists reduces the incidence of ESRD in patients with type II DM.^[122] Interestingly, the effects of angiotensin II receptor antagonists and ACEIs are independent of any antihypertensive property, which suggests a direct renal effect.

Furthermore, several new approaches, including the consumption of antifibrotic agents, endothelin receptor

antagonists, inhibitors of advanced glycation end-products (AGEs), receptor antagonists of advanced glycation end-products; growth factors and protein kinase C; oxidase inhibitors; NADPH; and glycosaminoglycans has shown promising results in preventing the progression of diabetic nephropathy.^[123]

IMPORTANCE OF BLOOD GLUCOSE CONTROL IN RENAL FAILURE PATIENTS

Although the importance of tight glycemic control has been noted in several small studies,^[124] large studies found no significant relationship between tight glycemic control and survival of dialysis patients. Moreover, tight control of blood glucose may increase the risk of hypoglycemic attacks.^[125,126] According to studies, tight monitoring of blood glucose seems to be less important in diabetic dialysis patients than in those without renal failure because of the following reasons:

1. Tight glycemic control increases the risk of hypoglycemia in dialysis patients, especially patients with reduced appetite;
2. Symptoms of hyperglycemia in dialysis patients are less than those in patients without kidney failure. Despite these evidences, some researchers suggest that damage to organs such as the eyes and heart will increase if blood sugar levels do not stay within an acceptable range.

Therefore, based on the recent scientific evidence, it is recommended that glycemic control be considered as the main therapeutic goal in the treatment of diabetic patients with ESRD, too.^[127]

Monitoring of blood glucose level in patients with ESRD is also important because a significant percentage of dialysis patients may get diabetes after the initiation of dialysis. Therefore, monitoring of blood glucose levels will help in early detection. This should be even more serious for patients with peritoneal dialysis because of their exposure to high glucose concentrations during peritoneal dialysis. For example, in a study conducted on 252 nondiabetic patients who received peritoneal dialysis, after 1 month the blood sugar level in 8% of them was higher than 200 mg/dL. This study also showed an inverse relationship between 3-year survival of patients and poorly controlled blood sugar.^[128]

According to the studies, if patients with type 2 diabetes have a fasting blood sugar less than 120 and glycosylated hemoglobin (HbA1c) of 5.6-7%, adequate control of glucose levels is required.^[129]

METABOLISM OF HYPERGLYCEMIC MEDICATIONS IN ESRD PATIENTS

In addition to insulin required for the treatment of diabetes, there are many types of oral medications available. Thus, it

is essential to know the metabolism of these drugs in ESRD patients, and they are briefly discussed below.

Sulfonylureas

Sulfonylureas, which are widely used to treat type 2 diabetes, stimulate insulin secretion from pancreatic beta cells. These drugs inhibit the adenosine triphosphate (ATP)-dependent channels by binding to their receptors in pancreatic beta cells, leading to calcium influx and stimulation of insulin secretion. Thus, sulfonylureas are only effective in diabetic patients with some remaining beta cell function. These drugs have been reported to increase tissue sensitivity to insulin, but the clinical importance of this effect is negligible. Sulfonylureas usually lower blood glucose levels by 20% and HbA1c levels by 1.5-2%. These drugs are usually used in patients whose weight is normal or slightly increased. These drugs should not be used in patients who are losing weight, or are ketotic despite adequate caloric intake. In these cases, insulin should be used.^[130,131]

Today, second-generation sulfonylureas including glibenclamide, gliclazide, glipizide, and glimepiride have largely replaced with the first generation including chlorpropamide, tolazamide, and tolbutamide.

Chlorpropamide and tolbutamide are substantially excreted by the kidney in patients with normal renal function, but in patients with chronic kidney disease, the elevated serum levels caused by these drugs may cause severe hypoglycemia. Active metabolites of glibenclamide are also excreted by the kidney and increased serum levels caused by them have been observed in patients with renal failure.^[56,61-63] Although glimepiride is metabolized by the liver, its active metabolites are excreted by the kidneys. Glimepiride is similar to glibenclamide in this aspect.^[132]

Although glipizide is metabolized in the liver, its inactive metabolites are renally excreted. Therefore, glipizide is considered the oral hypoglycemic drug of choice from this group of drugs for patients with CRF. It is recommended that drug dosage should be reduced to approximately 50% if the GFR is less than 50 cc/min. The recommended initial dose for patients with normal renal function is 2.5-5 mg per day and the maximum dose is 20-40 mg per day in some references. The recommended dose for patients with renal failure is 2.5-10 mg per day.^[133]

A low dose of glibenclamide can be given to patients with a GFR above 50 cc/min, but it should be avoided entirely in patients with acute renal failure.^[133,134]

It should be noted that some drugs such as beta blockers, salicylates, and warfarin can separate sulfonylureas from the bonded proteins, which increases the amount of these drugs in blood; thus their glucose-lowering effects.^[135]

Biguanides

The only available drug in the biguanides class is metformin. Biguanides reduce glucose production and release by the liver, increase insulin-stimulated glucose uptake by all peripheral tissues such as muscles, and decrease plasma levels of free fatty acids, and thus gluconeogenesis.

Like sulfonylureas, metformin typically reduces fasting plasma glucose levels by 20% and HbA1C by 1.5%. The most common side effects of metformin are gastrointestinal disorders, including a metallic taste in the mouth, mild anorexia, nausea, and diarrhea, which cause treatment to be discontinued in 5% of cases. The most serious side effect of metformin is lactic acidosis, which happens rarely.^[136,137]

The important factors that affect these complications are kidney, liver, and heart failures and kidney failure is the most important of them. This drug is usually excreted unchanged by the kidney, and its administration to patients with renal failure can cause drug retention and lactic acidosis. It is recommended to be avoided when GFR is less than 60 cc/min or serum creatinine is greater than 5.1 for men and 4.1 for women.^[138-140]

Thiazolidinediones

Thiazolidinediones improve insulin sensitivity by increasing glucose utilization in the liver, skeletal muscle, and adipose tissues; suppress hepatic production of glucose through binding to peroxisome proliferator-activated receptors (PPARs); and increase insulin secretion through improvement of pancreatic beta cell function.^[132,134]

Rosiglitazone and pioglitazone, the two main drugs of the thiazolidinedione family display strong protein-binding capacity, especially for albumin. Both these drugs and their metabolites are not retained in kidney failure; however, they can cause heart failure in patients receiving insulin.^[132,133]

In a study, rosiglitazone increased mortality from cardiovascular diseases in dialysis patients. The administration of these drugs should be avoided in patients with ESRD, especially if they also have heart failure.^[141]

Alpha-glucosidase inhibitors

The alpha-glucosidase inhibitors such as acarbose and miglitol reduce postprandial hyperglycemia by delaying the absorption of carbohydrate from the small intestine. The plasma levels of acarbose and its metabolites increase in patients with renal failure, but their relationship with an increased risk of hypoglycemia has not been established. Miglitol is also significantly excreted by the kidneys and expected to increase in the serum of patients with renal failure, so their administration is not recommended in patients with renal insufficiency.^[134]

Meglitinides

Nateglinide and repaglinide are relatively new drugs in the meglitinides class that are used to treat diabetes. They are short-acting blood glucose-lowering medicines. Although their structural features and receptors are different from sulfonylurea, they also increase insulin secretion from pancreatic beta cells through ATP-dependent potassium channels.^[134]

The recommended dose of repaglinide for people with normal renal function who have not previously received blood glucose-lowering agents is 50 mg before meals and the maximum dose is 40 mg before every meal. The suggested dose of nateglinide is 120 mg before every meal.

Although nateglinide is metabolized by the liver, its active metabolites are excreted by the kidney. In renal failure, active metabolites accumulate and cause hypoglycemia, so this drug should be used carefully or not prescribed in patients with renal failure.^[142,143]

Repaglinide is also metabolized by the liver, but less than 10% of its metabolites are eliminated renally. Thus its use may be allowed in patients with ESRD.^[89] A study showed that the risk of hypoglycemia for patients with ESRD receiving this drug was higher than that for patients with normal renal functions. Therefore the recommended starting dose of this drug for patients with renal failure is 0.5 mg per day and it should be increased carefully if a higher dose is required.^[144]

Insulin

The renal and hepatic metabolism of insulin is decreased in CRF, so its recommended dose should be reduced in the following manner:^[133,134]

When the GFR is above 50 mL/min, no dose reduction is required. When the GFR is 10-50 mL/min, the insulin dose should be reduced to approximately 75%. When the GFR is less than 10-50 mL/min, the dose should be reduced to approximately 50%. These adjustments are general, and insulin dosage adjustments should be based on regular blood glucose measurements. It should be noted that correction of uremia with dialysis on the one hand reduces insulin resistance and on the other hand increases insulin degradation; the ultimate effect of these on glycemic control in patients is different and glycemic control should be based on the final effect.^[118,145-161]

CONCLUSION

In early stages of renal failure, insulin secretion and resistance in peripheral tissues, primarily in skeletal muscle, is reduced, and in advanced stages of renal failure, renal

clearance is reduced. These facts are clinically important in the treatment of diabetes. Although insulin resistance increases the insulin requirement, decreased insulin degradation reduces the need for administration of insulin in diabetic patients with advanced CRF, which increases the risk of hypoglycemia.

Severe hyperglycemia in oliguric or anuric ESRD patients is not associated with features of osmotic diuresis, which is seen in patients without renal failure, but it can cause hyponatremia, hyperkalemia, and acute increase in the intravascular volume.

In several large studies on ESRD patients, there was no correlation between increased survival and tight blood glucose control of patients. It is suggested that the incidence of hypoglycemia was significantly higher in patients receiving strict glycemic control. It is recommended that blood sugar control be considered an important goal in the treatment of ESRD diabetic patients to prevent additional damage to other organs including the eyes, kidneys, and heart.

The factors determining perfect glycemic control are the following: Fasting blood sugar less than 126 mg/dL, 1-h postprandial blood glucose less than 200 mg/dL, and HbA1c 7-6 in patients with type 1 diabetes and 7-8 in patients with type 2 diabetes.

Glipizide, an oral hypoglycemic agent, is administered at a daily dose of 2.5-10 mg in patients with CRF. Although thiazolidines and their metabolites are not retained in kidney failure, they can lead to edema and cardiac failure, particularly in patients receiving insulin. Hence their use has been prohibited in patients with advanced renal failure, particularly if they also have heart failure. Repaglinide is mainly metabolized by the liver, and less than 10% of its metabolites are excreted by the kidneys. Thus its use in ESRD patients may be allowed with meticulous care and with regard to the risk of hypoglycemia. Lactic acidosis is a rare but potentially fatal complication of metformin, so the administration of this drug should also be avoided in CRF patients. Insulin can be administered subcutaneously or intraperitoneally in patients on peritoneal dialysis with safety and accurate monitoring. DM induces renal failure, which increases oxidative stress and oxidative aggravate them. Therefore, the use of antioxidants, especially the ones which are effective in treating these two diseases,^[118-123] should be beneficial.

Acknowledgments

There was no financial support for this manuscript.

Financial support and sponsorship

There was no funding for this manuscript.

Conflicts of interest

Neither MRK nor HN has any conflicts to disclose.

AUTHOR'S CONTRIBUTION

MRK drafted the manuscript and performed the literature search. HN provided critical revisions of the manuscript.

REFERENCES

1. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. *N Engl J Med* 2010;362:56-65.
2. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. *Kidney Int* 2006;69:375-82.
3. Ardalan MR, Nasri H. Lessons from our paleolithic primogenitors; a short look to the world diabetes day 2014 with the theme of "healthy living and diabetes". *J Parathyroid Dis* 2014;2:57-8.
4. Rahimi Z, Mansouri Zaveleh O, Rahimi Z, Abbasi A. AT2R -1332 G: A polymorphism and diabetic nephropathy in type 2 diabetes mellitus patients. *J Renal Inj Prev* 2013;2:97-101.
5. Einollahi B. Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients? *J Nephropathol* 2012;1:65-8.
6. Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; a literature review. *J Nephropathol* 2014;3:51-6.
7. Moradi M, Rahimi Z, Amiri S, Rahimi Z, Vessal M, Nasri H. AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy. *J Nephropathol* 2015;4:69-76.
8. Arashnia R, Roohi-Gilani K, Karimi-Sari H, Nikjoo N, Bahramifar A. Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomized clinical trial. *J Nephropathol* 2015;4:48-53.
9. Nasri H, Ghorbani A. Does erythropoietin slow progression of chronic kidney disease? *J Renal Inj Prev* 2013;2:81-2.
10. Roozbeh J, Sagheb MM, Vafaie E. The association between blood pressure level and serum uric acid concentration in hemodialysis patients. *J Nephropathol* 2015;4:85-90.
11. Tamadon MR, Zahmatkesh M. World kidney day 2015. *J Parathyroid Dis* 2015;3:34-6.
12. Kari J. Epidemiology of chronic kidney disease in children. *J Nephropathol* 2012;1:162-3.
13. Tamadon MR, Ardalan MR, Nasri H. World Kidney Day 2013; acute renal injury; a global health warning. *J Parathyroid Dis* 2013;1:27-8.
14. Assadi F. Psychological impact of chronic kidney disease among children and adolescents: Not rare and not benign. *J Nephropathol* 2013;2:1-3.
15. Junaid Nazar CM, Kindratt TB, Ahmad SM, Ahmed M, Anderson J. Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. *J Renal Inj Prev* 2014;3:61-7.
16. Motamedi P, Dehghani N, Kiani F, Taheri Z, Torkamaneh S, Nasri H. New concepts in diabetic kidney disease. *J Nephropharmacol* 2015;4:47-8.
17. Nasri H. The awareness of chronic kidney disease and aging; the focus of world kidney day in 2014. *J Nephropharmacol* 2014;3:1-2.
18. Hernandez GT, Nasri H. World Kidney Day 2014: Increasing awareness of chronic kidney disease and aging. *J Renal Inj Prev* 2013;3:3-4.
19. USRDS: The United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. *Am J Kidney Dis* 2010;55(Suppl 1):S1.

20. Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Vitamin D therapy in diabetic kidney disease; current knowledge on a public health problem. *J Parathyroid Dis* 2014;2:15-7.
21. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. *Diabetes* 2002;51:1226-32.
22. Einollahi B, Motalebi M, Salehi M, Ebrahimi M, Taghipour M. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: A review on current findings. *J Nephropathol* 2014;3:139-48.
23. Hajivandi A, Amiri M. World diabetes day 2013: Diabetes mellitus and nephrology. *J Nephropharmacol* 2013;2:31-2.
24. Rafieian-Kopaei M, Nasri H. Silymarin and diabetic nephropathy. *J Renal Inj Prev* 2012;1:3-5.
25. Tolouian R, Hernandez G. Prediction of diabetic nephropathy: The need for a sweet biomarker. *J Nephropathol* 2013;2:4-5.
26. Baradaran A, Mardani S, Tamadon MR, Shahbazian H, Beladi Mousavi SS. Sevelamer, a phosphate-binding resin with beneficial effect in diabetic kidney disease; a modern paradigm shift. *J Parathyroid Dis* 2014;2:61-2.
27. Andrianesis V, Doupis J. The role of kidney in glucose homeostasis-SGLT2 inhibitors, a new approach in diabetes treatment. *Expert Rev Clin Pharmacol* 2013;6:519-39.
28. Nasri H. Consequences of hypomagnesemia in type 2 diabetes mellitus patients. *J Renal Inj Prev* 2014;3:99-100.
29. Shahbazian H, Rezaei I. Diabetic kidney disease; review of the current knowledge. *J Renal Inj Prev* 2013;2:73-80.
30. Nasri H. Comment on: Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. *J Renal Inj Prev* 2012;1:13-4.
31. Baradaran A. Lipoprotein (a), type 2 diabetes and nephropathy; the mystery continues. *J Nephropathol* 2012;1:126-9.
32. Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with chronic kidney disease. *J Biomed Biotechnol* 2012;2012:691369.
33. Behradmanesh S, Nasri P. Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. *J Renal Inj Prev* 2012;1:23-6.
34. Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. *Mol Cell Endocrinol* 2009;307:77-82.
35. Rafieian-Kopaei M, Hosseini M, Shirzad H. Comment on: Effect of pomegranate flower extract on cisplatin-induced nephrotoxicity in rats. *J Nephropathol* 2014;3:121-3.
36. Onuigbo MA, Agbasi N. Intraoperative hypotension — a neglected causative factor in hospital-acquired acute kidney injury; a Mayo Clinic Health System experience revisited. *J Renal Inj Prev* 2015;4:61-7.
37. Karimi A, Moradi MT. Total phenolic compounds and *in vitro* antioxidant potential of crude methanol extract and the corresponding fractions of *Quercus brantii* L. acorn. *J HerbMed Pharmacol* 2015;4:35-9.
38. Nasri H, Shirzad H. Toxicity and safety of medicinal plants. *J HerbMed Pharmacol* 2013;2:21-2.
39. Azadegan-Dehkordi F, Bagheri N, Shirzad H, Rafieian-Kopaei M. The role of Th1 and Th17 cells in glomerulonephritis. *J Nephropathol* 2015;4:32-7.
40. Rafieian-Kopaei M. Medicinal plants and the human needs. *J HerbMed Pharmacol* 2012;1:1-2.
41. Ahmadi-Renani S, Fasihi-Ramandi M, Ahmadi K. *Ganoderma lucidum*: A promising anti-inflammatory medicinal plant. *J HerbMed Pharmacol* 2014;3:67-8.
42. Nasri H, Behradmanesh S, Ahmadi A, Baradaran A, Nasri P, Rafieian-Kopaei M. Association of serum lipids with level of blood pressure in type 2 diabetic patients. *J Renal Inj Prev* 2013;3:43-6.
43. Rafieian-Kopaei M, Nasri H. Vitamin D therapy in diabetic kidney disease. *J Nephropharmacol* 2014;3:3-4.
44. Mirhoseini M, Baradaran A, Rafieian-Kopaei M. Medicinal plants, diabetes mellitus and urgent needs. *J HerbMed Pharmacol* 2013;2:53-4.
45. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo controlled clinical trial. *J Nephropathol* 2014;3:29-33.
46. Behradmanesh S, Derees F, Rafieian-Kopaei M. Effect of *Salvia officinalis* on diabetic patients. *J Renal Inj Prev* 2013;2:51-4.
47. Beladi-Mousavi SS, Bashardoust B, Nasri H, Ahmadi A, Tolou-Ghamari Z, Hajian S. Serum uric acid level and its association with cardio-metabolic risk factors in prediabetics. *J Parathyroid Dis* 2014;2:51-2.
48. Sadeghi M, Khosravi-Boroujeni H, Sarrafzadegan N, Asgary S, Roohafza H, Gharipour M, *et al.* Cheese consumption in relation to cardiovascular risk factors among Iranian adults- IHHP Study. *Nutr Res Pract* 2014;8:336-41.
49. Nasri H, Ardalan MR, Rafieian-Kopaei R. On the occasion of world hypertension day 2014. *J Parathyroid Dis* 2014;2:19-20.
50. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. *J Nephropathol* 2014;3:99-104.
51. Nasri H, Behradmanesh S, Maghsoudi AR, Ahmadi A, Nasri P, Rafieian-Kopaei M. Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus; a randomized double blind clinical trial. *J Renal Inj Prev* 2013;3:31-4.
52. Rafieian-kopaei M, Keshvari M, Asgary S, Salimi M, Heidarian E. Potential role of a nutraceutical spice (*Allium hirtifolium*) in reduction of atherosclerotic plaques. *J HerbMed Pharmacol* 2013;2:23-8.
53. Ghasemi-Pirbaluti M, Pourghesari B, Shirzad H, Motaghi E, Askarian Dehkordi N, Surani Z, *et al.* Effect of Epigallocatechin-3-gallate (EGCG) on cell proliferation inhibition and apoptosis induction in lymphoblastic leukemia cell line. *J HerbMed Pharmacol* 2015;4:65-8.
54. Shirzad H, Shahrani M, Rafieian-Kopaei M. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes *in vivo*. *Int Immunopharmacol* 2009;9:968-70.
55. Aghaei M, Ghanadian M, Faez F, Esfandiary E. Cytotoxic activities of *Euphorbia kopetdaghi* against OVCAR-3 and EJ-138 cell lines. *J HerbMed Pharmacol* 2015;4:49-52.
56. Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy. *J Renal Inj Prev* 2013;2:9-10.
57. Sajjadi SE, Ghanadian M, Haghighi M, Mouhebat L. Cytotoxic effect of *Cousinia verbascifolia* Bunge against OVCAR-3 and HT-29 cancer cells. *J HerbMed Pharmacol* 2015;4:15-9.
58. Shirzad H, Kiani M, Shirzad M. Impacts of tomato extract on the mice fibrosarcoma cells. *J HerbMed Pharmacol* 2013;2:13-6.
59. Shirzad H, Taji F, Rafieian-Kopaei M. Correlation between antioxidant activity of garlic extracts and WEHI-164 fibrosarcoma tumor growth in BALB/c mice. *J Med Food* 2011;14:969-74.
60. Sarteshnizi NA, Dehkordi MM, Farsani SK, Teimori H. Anticancer activity of ethanolic extract of propolis on AGS cell line. *J HerbMed Pharmacol* 2015;4:29-34.
61. Sarrafchi A, Bahmani M, Shirzad H, Rafieian-Kopaei M. Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants. *Curr Pharm Des* 2015 Nov 12. [Epub ahead of print].
62. Baradaran A, Rabiei Z, Rafieian M, Shirzad H. A review study on medicinal plants affecting amnesia through cholinergic system. *J HerbMed Pharmacol* 2012;1:3-9.

63. Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoprotective efficacy. *J Renal Inj Prev* 2013;2:35-6.
64. Bahmani M, Sarrafchi A, Shirzad H, Rafieian-Kopaei M. Autism: Pathophysiology and promising herbal remedies. *Curr Pharm Des* 2015 Nov 12. [Epub ahead of print].
65. Nasri H, Ahmadi A, Baradaran A, Nasri P, Hajian S, Pour-Arian A, *et al*. A biochemical study on ameliorative effect of green tea (*Camellia sinensis*) extract against contrast media induced acute kidney injury. *J Renal Inj Prev* 2013;3:47-9.
66. Sotodeh-Asl N, Tamadon MR, Malek F, Zahmatkesh M. Vitamin D deficiency and psychological disorders. *J Parathyr Dis* 2014;2:21-5.
67. Bahmani M, Rafieian M, Baradaran A, Rafieian S, Rafieian-kopaei M. Nephrotoxicity and hepatotoxicity evaluation of *Crocus sativus* stigmas in neonates of nursing mice. *J Nephrothol* 2014;3:81-5.
68. Nasri H. Renoprotective effects of garlic. *J Renal Inj Prev* 2013;2:27-8.
69. Ansari R, Shahinfard N, Namjou A, Rafieian M, Shirzad H, Rafieian-kopaei M. Ameliorative property of *Teucrium polium* on second degree burn. *J HerbMed Pharmacol* 2013;2:9-11.
70. Bahmani M, Vakili-Saatloo N, Maghsoudi R, Momtaz H, Saki K, Kazemi-Ghoshchi B, *et al*. A comparative study on the effect of ethanol extract of wild *Scrophularia deserti* and streptomycin on *Brucella melitensis*. *J HerbMed Pharmacol* 2013;2:17-20.
71. Modaresi M, Pouriyanzadeh A, Asadi-Samani M. Antiepileptic activity of hydroalcoholic extract of basil in mice. *J HerbMed Pharmacol* 2014;3:57-60.
72. Bagheri N, Taghikhani A, Rahimian G, Salimzadeh L, Azadegan Dehkordi F, Zandi F, *et al*. Association between virulence factors of *helicobacter pylori* and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. *Microb Pathog* 2013;65:7-13.
73. Kheirabadi KP, Dehkordi SS, Kheibari P. Effect of *Kelussia odoratissima* Mozaff essential oil on promastigot form of *Leishmania major* (*in vitro*). *J HerbMed Pharmacol* 2015;4:10-4.
74. Hosseinpour M, Mobini-Dehkordi M, Saffar B, Teimori H. Antiproliferative effects of *Matricaria chamomilla* on *Saccharomyces cerevisiae*. *J HerbMed Pharmacol* 2013;2:49-51.
75. Moghim H, Taghipoor S, Shahinfard N, Kheiri S, Heydari Z, Rafieian S. Antifungal effects of *Allium ascalonicum*, *Marticularia chamomilla* and *Stachys lavandulifolia* extracts on *Candida albicans*. *J HerbMed Pharmacol* 2014;3:9-14.
76. Amanpour R, Abbasi-Maleki S, Neyriz-Naghadehi M, Asadi-Samani M. Antibacterial effects of *Solanum tuberosum* peel ethanol extract *in vitro*. *J HerbMed Pharmacol* 2015;4:45-8.
77. Bahmani M, Vakili-Saatloo N, Gholami-Ahangaran M, Karamati SA, Banihabib E, Hajigholizadeh G, *et al*. A comparison study on the anti-leech effects of onion (*Allium cepa* L) and ginger (*Zingiber officinale*) with levamisole and triclabendazole. *J HerbMed Pharmacol* 2013;2:1-3.
78. Sharafati-chalesshtori R, Rafieian-kopaei M. Screening of antibacterial effect of the *Scrophularia Striata* against *E. coli* *in vitro*. *J HerbMed Pharmacol* 2014;3:31-4.
79. Jabari M, Asghari G, Ghanadian M, Jafari A, Yousefi H, Jafari R. Effect of *Chaerophyllum macropodum* extracts on *Trichomonas vaginalis* *in vitro*. *J HerbMed Pharmacol* 2015;4:61-4.
80. Mardani S, Nasri H, Rafieian-Kopaei M, Beladi Mousavi SS. Hyperuricemia; a new look at an old problem. *J Nephropharmacol* 2012;1:13-4.
81. Momeni A. Serum uric acid and diabetic nephropathy. *J Renal Inj Prev* 2012;1:37-8.
82. Mardani S, Nasri H, Hajian S, Ahmadi A, Kazemi R, Rafieian-Kopaei M. Impact of *Momordica charantia* extract on kidney function and structure in mice. *J Nephrothol* 2014;3:35-40.
83. Rahimi Z. Parathyroid hormone, glucose metabolism and diabetes mellitus. *J Parathyr Dis* 2014;2:55-6.
84. Rahimi-Madiseh M, Heidarian E, Rafieian-kopaei M. Biochemical components of *Berberis lycium* fruit and its effects on lipid profile in diabetic rats. *J HerbMed Pharmacol* 2014;3:15-9.
85. Rahimi Z. ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. *J Nephrothol* 2012;1:143-51.
86. Roshan B, Stanton RC. A story of microalbuminuria and diabetic nephropathy. *J Nephrothol* 2013;2:234-40.
87. Kalantar Zadeh K. A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. *Counterpoint. Diabetes Care* 2012;35:1625-8.
88. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. *Am J Kidney Dis* 2002;40:566-75.
89. Stanton RC. Oxidative stress and diabetic kidney disease. *Curr Diab Rep* 2011;11:330-6.
90. Ghorbani A, Rafieian-Kopaei M, Nasri H. Lipoprotein (a): More than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. *J Nephrothol* 2013;2:67-70.
91. Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Impact of vitamin D on the immune system in kidney disease. *J Parathyr Dis* 2013;1:17-20.
92. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. *J Renal Inj Prev* 2014;3:109-10.
93. Rafieian-Kopaei M, Baradaran A. *Teucrium polium* and kidney. *J Renal Inj Prev* 2013;2:3-4.
94. Jafarpour N, Abbasi-Maleki S, Asadi-Samani M, Khayatnouri MH. Evaluation of antidepressant-like effect of hydroalcoholic extract of *Passiflora incarnata* in animal models of depression in male mice. *J HerbMed Pharmacol* 2014;3:41-5.
95. Baradaran A, Nasri H, Nematbakhsh M, Rafieian-Kopaei M. Antioxidant activity and preventive effect of aqueous leaf extract of *Aloe Vera* on gentamicin-induced nephrotoxicity in male Wistar rats. *Clin Ter* 2014;165:7-11.
96. Khoshdel A, Famuri F, Keivani E, Lotfizadeh M, Kasiri KA, Rafieian M. The effect of aqueous *Elaeagnus angustifolia* extract on acute non-inflammatory diarrhea in 1-5 year old children. *J HerbMed Pharmacol* 2014;3:53-6.
97. Lala MA, Nazar CM, Lala HA, Singh JK. Interrelation between blood pressure and diabetes. *J Renal Endocrinol* 2015;1:e05.
98. Baharara J, Balanejad SZ, Kamareh E, Asadi-Samani M. The effects of green tea extract on teratogenicity induced by low frequency electromagnetic field on bone marrow Balb/C mice embryo. *J HerbMed Pharmacol* 2014;3:47-51.
99. Rafieian-Kopaei M. Medicinal plants for renal injury prevention. *J Renal Inj Prev* 2013;2:63-5.
100. Ardalan MR, Rafieian-Kopaei M. Antioxidant supplementation in hypertension. *J Renal Inj Prev* 2013;3:39-40.
101. Ardalan MR, Rafieian-Kopaei M. Is the safety of herbal medicines for kidneys under question? *J Nephropharmacol* 2013;2:11-2.
102. Kooti W, Moradi M, Akbari SA, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D. Therapeutic and pharmacological potential of *Foeniculum vulgare* Mill: A review. *J HerbMed Pharmacol* 2015;4:1-9.
103. Nasri H, Rafieian-kopaei M, Shirzad M, Rafieian M, Sahinfard Rafieian S. Effects of *Allium sativum* on liver enzymes and atherosclerotic risk factors. *J HerbMed Pharmacol* 2013;2:23-8.
104. Aboutari J, Haydarnejad MS, Fatahian Dehkordi R, Vanani SR. Histomorphometric study on the effects of *Artemisia sieberi* extract in mice skin. *J HerbMed Pharmacol* 2015;4:20-4.

105. Sewell RD, Rafeiean-Kopaei M. The history and ups and downs of herbal medicine usage. *J HerbMed Pharmacol* 2014;3:1-3.
106. Tavafi M. Suggestions for attenuation of renal ischemia reperfusion injury based on mechanisms involved in epithelial cells damages. *J Nephropharmacol* 2015;4:1-3.
107. Ardalan MR, Nasri H. Acute kidney injury; the focus of world kidney day in 2013. *J Nephropharmacol* 2013;2:15-6.
108. Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. *J Parathyroid Dis* 2014;2:3-4.
109. Baradaran A, Rafeiean-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. *J Renal Inj Prev* 2013;2:15-21.
110. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigations. *J Renal Inj Prev* 2013;2:59-62.
111. Tavafi M. Diabetic nephropathy and antioxidants. *J Nephrothol* 2013;2:20-7.
112. Tamadon MR, Baradaran A, Rafeiean-Kopaei M. Antioxidant and kidney protection; differential impacts of single and whole natural antioxidants. *J Renal Inj Prev* 2013;3:41-2.
113. Nasri H, Rafeiean-Kopaei M. Herbal medicine and diabetic kidney disease. *J Nephropharmacol* 2013;2:1-2.
114. Rafeiean-Kopaei M, Baradaran A, Rafeiean-Kopaei M. Plants antioxidants: From laboratory to clinic. *J Nephrothol* 2013;2:152-3.
115. Khajehdehi P. Turmeric: Reemerging of a neglected Asian traditional remedy. *J Nephrothol* 2012;1:17-22.
116. Rafeiean-Kopaei M, Motamedi P, Vakili L, Dehghani N, Kiani F, Taheri Z, *et al.* Green tea and type 2 diabetes mellitus. *J Nephropharmacol* 2014;3:21-3.
117. Spasovski D. Renal markers for assessment of renal tubular and glomerular dysfunction. *J Nephropharmacol* 2013;2:23-5.
118. Soleimani AR, Akbari H, Soleimani S, Beladi Mousavi SS, Tamadon MR. Effect of sour tea (Lipicom) pill versus captopril on the treatment of hypertension. *J Renal Inj Prev* 2015;4:73-9.
119. Rafeiean-Kopaei M. Natural sources of vitamin D. *J Parathyroid Dis* 2015;3:10-1.
120. Hajian S. Renoprotective effects of green tea. *J Nephropharmacol* 2013;2:21-2.
121. Ardalan MR, Ghafari A, Hamzavi F, Nasri H, Baradaran B, Majidi J, *et al.* Antiphospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. *J Nephrothol* 2013;2:241-8.
122. Atkins RC, Zimmet P; 2010 International Society of Nephrology/ International Federation of Kidney Foundations World Kidney Day Steering Committee and the International Diabetes Federation. Diabetic kidney disease: Act now or pay later. *Am J Med Sci* 2010;339:102-4.
123. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. *Am J Kidney Dis* 2010;55:928-40.
124. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, *et al.* Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. *Diabetes Care* 2006;29:1496-500.
125. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. *Am J Kidney Dis* 2010;55:875-84.
126. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent Cox model analyses. *Clin J Am Soc Nephrol* 2010;5:1595-601.
127. Behradmanesh S, Nasri H. Association of serum calcium with level of blood pressure in type 2 diabetic patients. *J Nephrothol* 2013;2:254-7.
128. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. *Am J Kidney Dis* 2007;49:524-32.
129. Nasri H. On the occasion of the world diabetes day 2013; diabetes education and prevention; a nephrology point of view. *J Renal Inj Prev* 2013;2:31-2.
130. Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatment. *Ann Emerg Med* 2001;38:68-78.
131. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: Mechanisms, clinical implications, and drug interactions. *J Diabetes Complications* 2003;17(Suppl):11-5.
132. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. *Am J Kidney Dis* 2007;50:865-79.
133. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, *et al.* Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2011;80:1122-37.
134. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. *Semin Dial* 2004;17:365-70.
135. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. *Diabetes* 2002;51(Suppl 3):S368-76.
136. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. *Drugs* 2005;65:385-411.
137. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. *J Biol Chem* 2002;277:25226-32.
138. Beladi Mousavi SS, Nasri H, Rafeiean-Kopaei M, Tamadon MR. Metformin improves diabetic kidney disease. *J Nephropharmacol* 2012;1:1-2.
139. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. *Diabetes Care* 2008;31:2086-91.
140. Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, *et al.* The role of metformin in metformin-Associated Lactic Acidosis (MALA): Case series and formulation of a model of pathogenesis. *Drug Saf* 2013. [Epub ahead of print].
141. Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, *et al.* Rosiglitazone is associated with mortality in chronic hemodialysis patients. *J Am Soc Nephrol* 2009;20:1094-101.
142. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, *et al.* Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. *Clin Nephrol* 2003;60:90-5.
143. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. *Diabetes Res Clin Pract* 2003;59:191-4.
144. Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. *Diabetes Care* 2003;26:886-91.
145. Nasri H, Ahmadi A, Baradaran A, Momeni A, Nasri P, Mardani S, *et al.* Clinicopathological correlations in lupus nephritis; a single center experience. *J Nephrothol* 2014;3:115-20.
146. Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. *Cochrane Database Syst Rev* 2008;CD006297.
147. Mardani S, Nasri H. Catastrophic antiphospholipid syndrome presenting with sudden renal failure and past history of long-lasting psychosis and hypertension in a 42 years woman. *J Nephrothol* 2013;2:110-3.

148. Nasri H, Ahmadi A, Rafieian-Kopaei M, Bashardoust B, Nasri P, Mubarak M. Association of glomerular C4d deposition with various demographic data in IgA nephropathy patients; a preliminary study. *J Nephropathol* 2015;4:19-23.
149. Momeni A, Nasri H. Concurrent diabetic nephropathy and C1q nephropathy in a young male patient: The first report in literature. *J Nephropathol* 2013;2:201-3.
150. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, *et al.* Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. *Diabetes Care* 2005;28:10-4.
151. Khodadadi S. Role of herbal medicine in boosting immune system. *Immunopathol Persa* 2015;1:e01.
152. Mubarak M, Nasri H. What nephrologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions? *J Nephropathol* 2014;3:4-8.
153. Kafeshani M. Ginger, micro-inflammation and kidney disease. *J Renal Endocrinol* 2015;1:e04.
154. Hajian SH. Positive effect of antioxidants on immune system. *Immunopathol Persa* 2015;1:e02.
155. Nasri H. Deposition of complement in the vessels of immunoglobulin A nephropathy patients. *Immunopathol Persa* 2015;1:e03.
156. Ahmadi A, Soori H. Important statistical points to improve and promote the methodology of the articles on medical sciences, particularly nephrology and kidney; a review article. *J Renal Inj Prev* 2015;4:4-8.
157. Nasri H, Mubarak M. Extracapillary proliferation in IgA nephropathy; recent findings and new ideas. *J Nephropathol* 2015;4:1-5.
158. Bah AO, Lamine C, Balde MC, Bah ML, Rostaing L. Epidemiology of chronic kidney diseases in the Republic of Guinea; future dialysis needs. *J Nephropathol* 2015;4:127-33.
159. Rafieian-Kopaei M, Baradaran A. On the occasion of world diabetes day 2105; act today to change tomorrow. *J Renal Endocrinol* 2015;1:e02.
160. Nasri H. Hypertension and renal failure with right arm pulse weakness in a 65 years old man. *J Nephropathol* 2012;1:130-3.
161. Nouri P, Nasri H. Irisin and kidney disease; new concepts. *J Renal Endocrinol* 2015;1:e03.